Omnicell Q3 Earnings Call Highlights

Key Points

• Omnicell exceeded third-quarter guidance, reporting $308 million in revenue, $45 million in non-GAAP EBITDA and $0.58 in non-GAAP EPS. The company attributed the EBITDA outperformance to cost efficiencies, favorable product mix, stronger margins and disciplined spending.
• Titan XT shipments are set to begin within days, while the OmniSphere cloud platform remains on track for general availability in the first half of 2027. Existing XT customers will be able to access OmniSphere through an XTExtend console upgrade without immediately replacing their hardware.
• Omnicell raised its full-year 2026 non-GAAP EBITDA outlook to $187 million-$193 million and EPS outlook to $2.48-$2.56, while narrowing revenue guidance to $1.225 billion-$1.231 billion. Management maintained product bookings guidance of $425 million-$560 million but cautioned that customer purchasing timelines remain variable and memory-chip costs elevated.

Omnicell NASDAQ: OMCL reported third-quarter 2026 revenue and non-GAAP EBITDA above the high end of its prior guidance, while executives said the company is preparing to begin shipments of its Titan XT automated dispensing hardware and remains on track for first-half 2027 general availability of its OmniSphere cloud platform.

Total third-quarter revenue was $308 million, exceeding the company’s guidance range of $301 million to $307 million. Product revenue was approximately $173 million and service revenue was approximately $135 million. Non-GAAP EBITDA reached $45 million, above Omnicell’s forecast of $32 million to $37 million, while non-GAAP earnings per share was $0.58.

Chairman, Chief Executive Officer and Founder Randall Lipps said the results reflected an execution-focused approach and supported the company’s confidence in its autonomous medication-management strategy. He said medication management remains a priority investment for health systems seeking operational efficiency, reliability and relief from staffing pressures.

Titan XT shipments set to begin

President and Chief Operating Officer Nnamdi Njoku said Omnicell was days away from its first Titan XT hardware shipment, consistent with the second-half 2026 schedule previously outlined by the company. Revenue to date has primarily been from the existing XT platform, he said, with only a modest contribution from Titan XT expected in 2026.

Titan XT is designed as a scalable and cybersecure automated dispensing platform, while OmniSphere is intended to provide cloud-based enterprise visibility, workflow tools and actionable insights. Njoku said the company views the hardware and software offerings as complementary and expects them to be evaluated together by customers.

OmniSphere is scheduled for general availability in the first half of 2027. The company expects adoption of the platform to build over subsequent years as customers migrate from locally maintained servers to cloud-native technology.

Omnicell is also providing an upgrade path for existing XT customers that are not yet ready to refresh their cabinet hardware. Through an XTExtend console upgrade, those customers can gain access to OmniSphere without moving immediately to Titan XT, Njoku said.

The company said its sales pipeline has grown since the prior earnings call and includes opportunities across a range of deal sizes. Executives said customer evaluations increasingly involve cross-functional planning, technical architecture, contracting and deployment discussions, reflecting longer decision processes for enterprise-wide offerings.

Leasing and competitive opportunities

Management said leasing has become a meaningful component of Omnicell’s go-to-market strategy, particularly in competitive opportunities. Chief Financial Officer Baird Radford said leasing helps move conversations beyond whether a customer can fund a project and toward clinical capabilities and workforce efficiencies.

Radford estimated that roughly 30% of the marketplace is currently involved in leasing transactions, with the majority associated with customers of Omnicell’s primary competitor. He said leasing activity may be steady but could be uneven depending on the mix of customers and their financing preferences.

Under Omnicell’s sales-type lease structure, revenue is recognized upfront in a manner similar to a capital sale, Radford said. The company expects some initial gross-margin erosion at implementation, followed by interest income over the lease term that flows through product revenue.

Management reiterated full-year product bookings guidance of $425 million to $560 million. Radford said bookings are expected to be weighted toward the end of the year, and the timing of medium and large opportunities can be variable. The lower end of the range reflects uncertainty in customer purchase timing rather than a deterioration in demand, he said.

Executives said the company’s installed base is younger than its competitor’s on average, contributing to current activity among competitive opportunities. However, Njoku said the pace of market-share gains will depend on factors including health systems’ ability to manage implementation changes alongside other priorities.

Margins, cash flow and updated outlook

Radford attributed third-quarter EBITDA outperformance to cost efficiencies, favorable product customer mix, stronger gross margins in both product and service lines, disciplined spending and some expenses shifting into the fourth quarter. Omnicell ended the quarter with $315 million in cash and cash equivalents and generated $20 million of free cash flow.

The company said it has focused on improving operating leverage while maintaining investment in growth and innovation. Radford said EBITDA has grown meaningfully faster than revenue through the first three quarters of 2026, although top-line growth remains modest in the early stages of the refresh cycle.

Omnicell also said it continues to face higher memory-chip and related component costs. Of approximately $6 million in incremental second-half memory costs previously identified, about half affected the third quarter, with the remainder expected in the fourth quarter. The company expects the higher memory-cost environment to continue for the foreseeable future.

For the fourth quarter, Omnicell forecast:

• Total revenue of $295 million to $301 million.
• Non-GAAP EBITDA of $30 million to $36 million.
• Non-GAAP earnings per share of $0.41 to $0.49.

For full-year 2026, the company narrowed its revenue outlook to $1.225 billion to $1.231 billion, including product revenue of $684 million to $687 million and service revenue of $541 million to $544 million. It raised its non-GAAP EBITDA outlook to $187 million to $193 million and its non-GAAP EPS outlook to $2.48 to $2.56.

Omnicell tightened year-end annual recurring revenue guidance to $660 million to $670 million. Radford said the unchanged lower end and slightly reduced upper end reflected greater visibility into the timing of consumables-business growth opportunities. The company also said it anticipates a modest impact on 2026 ARR from developments involving the 340B Drug Pricing Program, primarily related to acute customer dynamics.

About Omnicell (NASDAQ:OMCL)

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company's product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.